AccScience Publishing / EJMO / Online First / DOI: 10.36922/EJMO026310397
Cite this article
7
Download
73
Views
Related Info Links
More by Authors Links
Journal Browser
Volume | Year
Issue
Search
News and Announcements
View All
ORIGINAL RESEARCH ARTICLE

Bioinformatic identification of a fatty acid metabolism-related gene signature for prognosis prediction and drug sensitivity assessment in osteosarcoma

Hao Gu1† ,  Changsheng Zhang1† ,  Yu Li1 ,  Chuanzhi Zhang2 ,  Xiao Shi1* ,  Xinxin Si1*
Show Less
1 Jiangsu Key Laboratory of Marine Pharmaceutical Compound Screening, Jiangsu Key Laboratory of Marine Biotechnology, Co-Innovation Center of Jiangsu Marine Bio-industry Technology, School of Pharmacy, Jiangsu Ocean University, Lianyungang, Jiangsu , China
2 Bio-Pharmaceutical Research Institute, Lian Yun Gang Chia Tai Tianqing Pharmaceutical Group Co., Ltd, Lianyungang, Jiangsu , China
†These authors contributed equally to this work.
Received: 29 July 2026 | Revised: 21 September 2026 | Accepted: 27 October 2026 | Published online: 17 November 2026
© 2026 by the Author(s). This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution -Noncommercial 4.0 International License (CC-by the license) ( https://creativecommons.org/licenses/by-nc/4.0/ )
Abstract

Introduction: Osteosarcoma is an aggressive malignancy with high metastatic potential, leading to poor prognosis in recurrent and metastatic cases.

Objectives: This study aimed to identify prognostic fatty acid metabolism-related genes (FAMRGs) in osteosarcoma and characterize the clinical and biological features of ACSF2.

Methods: Transcriptomic and clinical data from Therapeutically Applicable Research to Generate Effective Treatments–Osteosarcoma, Genotype-Tissue Expression, and GSE16088 were analyzed. Consistently differentially expressed FAMRGs were screened via dual-cohort validation. Least absolute shrinkage and selection operator and Cox regression analyses were used to select prognostic genes, with overall survival (OS) as the primary endpoint and event-free survival (EFS) as the secondary endpoint. An ACSF2-based prognostic model combined with metastatic status was internally validated by bootstrap resampling. Gene Set Enrichment Analysis, OncoPredict, ESTIMATE, and CIBERSORT analyses were performed to explore ACSF2-associated pathways, drug sensitivity, and immune infiltration. In vitro functional assays were conducted to verify the biological function of acyl-CoA synthetase family member 2 (ACSF2).

Results: Four prognostic FAMRGs were screened from 15 consistently dysregulated genes. Low ACSF2 expression independently predicted inferior OS and EFS, without significant correlation with diagnostic metastasis. The optimized model yielded a corrected C-index of 0.729 and a calibration slope of 0.943. ACSF2 was closely associated with fatty acid and mitochondrial metabolism. The ACSF2-high subgroup showed higher predicted sensitivity to Uprosertib and MN-64 and exhibited distinct immune infiltration patterns. Functional experiments confirmed that elevated ACSF2 expression suppresses the migration and invasion of human osteosarcoma cells.

Conclusion: ACSF2 is a promising candidate prognostic biomarker for osteosarcoma. Its metabolic, pharmacological, and immune correlations are exploratory and require further experimental validation.

Graphical abstract
Keywords
ACSF2
Fatty acid metabolism
Prognostic biomarker
Osteosarcoma
Funding
This study was supported by grants from the National Natural Science Foundation of China (81703557), A Project Funded by the Priority Academic Program Development of Jiangsu Higher Education Institutions (PAPD), and the College Student Innovation and Entrepreneurship Project.
Conflict of interest
The authors declare that they have no competing interests.
References
  1. Isakoff MS, Bielack SS, Meltzer P, Gorlick R. Osteosarcoma: current treatment and a collaborative pathway to success. J Clin Oncol. 2015;33(27):3029-3035. doi: 10.1200/JCO.2014.59.4895
  2. Meltzer PS, Helman LJ. New horizons in the treatment of osteosarcoma. N Engl J Med. 2021;385(22):2066-2076. doi: 10.1056/NEJMra2103423
  3. Sheng G, Gao Y, Yang Y, Wu H. Osteosarcoma and metastasis. Front Oncol. 2021;11:780264. doi: 10.3389/fonc.2021.780264
  4. Belayneh R, Fourman MS, Bhogal S, Weiss KR. Update on osteosarcoma. Curr Oncol Rep. 2021;23(6):71. doi: 10.1007/s11912-021-01053-7
  5. Panez-Toro I, Muñoz-García J, Vargas-Franco JW, et al. Advances in osteosarcoma. Curr Osteoporos Rep. 2023;21(4):330-343. doi: 10.1007/s11914-023-00803-9
  6. Hattinger CM, Patrizio MP, Fantoni L, Casotti C, Riganti C, Serra M. Drug resistance in osteosarcoma: emerging biomarkers, therapeutic targets and treatment strategies. Cancers (Basel). 2021;13(12):2878. doi: 10.3390/cancers13122878
  7. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144(5):646-674. doi: 10.1016/j.cell.2011.02.013
  8. Jin HR, Wang J, Wang ZJ, et al. Lipid metabolic reprogramming in tumor microenvironment: from mechanisms to therapeutics. J Hematol Oncol. 2023;16(1):103. doi: 10.1186/s13045-023-01498-2
  9. Dai CL, Qiu ZY, Wang AQ, Yan S, Zhang LJ, Luan X. Targeting cholesterol metabolism: a promising therapy strategy for cancer. Acta Pharmacol Sin. 2025;46(8):2093-2104. doi: 10.1038/s41401-025-01531-9
  10. Currie E, Schulze A, Zechner R, Walther TC, Farese RV Jr. Cellular fatty acid metabolism and cancer. Cell Metab. 2013;18(2):153-161. doi: 10.1016/j.cmet.2013.05.017
  11. Shi Y, Yue X, Luo Q. Metabolic reprogramming in osteosarcoma. Pediatr Discov. 2023;1(2):e18. doi: 10.1002/pdi3.18
  12. Wu Q, Chen H, Li J. Metabolic reprogramming-related drug resistance in osteosarcoma: from molecular mechanisms to therapeutic translation. Front Mol Biosci. 2026;13:1928880. doi: 10.3389/fmolb.2026.1928880
  13. Qian H, Lei T, Hu Y, Lei P. Expression of lipid-metabolism genes is correlated with immune microenvironment and predicts prognosis in osteosarcoma. Front Cell Dev Biol. 2021;9:673827. doi: 10.3389/fcell.2021.673827
  14. Zhang Y, He R, Lei X, et al. A novel pyroptosis-related signature for predicting prognosis and indicating immune microenvironment features in osteosarcoma. Front Genet. 2021;12:780780. doi: 10.3389/fgene.2021.780780
  15. Liu S, Wu B, Li X, Zhao L, Wu W, Ai S. Construction and validation of a potent epigenetic modification-related prognostic signature for osteosarcoma patients. J Oncol. 2021;2021(1):2719172. doi: 10.1155/2021/2719172
  16. Gul Mohammad A, Li D, He R, et al. Integrated analyses of an RNA-binding protein-based signature related to tumor immune microenvironment and candidate drugs in osteosarcoma. Am J Transl Res. 2022;14(4):2501-2526.
  17. Han J, Hu Y, Ding S, Liu S, Wang H. The analysis of the pyroptosis-related genes and hub gene TP63 ceRNA axis in osteosarcoma. Front Immunol. 2022;13:974916. doi: 10.3389/fimmu.2022.974916
  18. Henderson MX, Wirak GS, Zhang YQ, et al. Neuronal ceroid lipofuscinosis with DNAJC5/CSPα mutation has PPT1 pathology and exhibit aberrant protein palmitoylation. Acta Neuropathol. 2016;131(4):621-637. doi: 10.1007/s00401-015-1512-2
  19. Xu J, Su Z, Cheng X, et al. High PPT1 expression predicts poor clinical outcome and PPT1 inhibitor DC661 enhances sorafenib sensitivity in hepatocellular carcinoma. Cancer Cell Int. 2022;22(1):115. doi: 10.1186/s12935-022-02508-y
  20. Brun S, Bestion E, Raymond E, et al. GNS561, a clinical-stage PPT1 inhibitor, is efficient against hepatocellular carcinoma via modulation of lysosomal functions. Autophagy. 2022;18(3):678-694. doi: 10.1080/15548627.2021.1988357
  21. Shi H, Qi H, Xie D, et al. Inhibition of ACSF2 protects against renal ischemia/reperfusion injury via mediating mitophagy in proximal tubular cells. Free Radic Biol Med. 2023;198:68-82. doi: 10.1016/j.freeradbiomed.2023.02.003
  22. Luo L, Zhang S, Guo N, Li H, He S. ACSF2-mediated ferroptosis is involved in ulcerative colitis. Life Sci. 2023;313:121272. doi: 10.1016/j.lfs.2022.121272
  23. Zhang Y, Qiao Z, He M, Xia J. OGT promotes the ferroptosis of chondrocytes in osteoarthritis development via O-GlcNAcylation modification of ACSF2. Immunol Res. 2025;73(1):7. doi: 10.1007/s12026-024-09567-5
  24. Wang H, Cheng Q, Chang K, Bao L, Yi X. Integrated analysis of ferroptosis-related biomarker signatures to improve the diagnosis and prognosis prediction of ovarian cancer. Front Cell Dev Biol. 2022;9:807862. doi: 10.3389/fcell.2021.807862
  25. Peng X, Zhao H, Ye L, et al. Biomarker identification and risk prediction model development for differentiated thyroid carcinoma lung metastasis based on primary lesion proteomics. Clin Cancer Res. 2024;30(14):3059-3072. doi: 10.1158/1078-0432.CCR-23-3806
  26. Dumble M, Crouthamel MC, Zhang SY, et al. Discovery of novel AKT inhibitors with enhanced anti-tumor effects in combination with the MEK inhibitor. PLoS One. 2014;9(6):e100880. doi: 10.1371/journal.pone.0100880
  27. Narwal M, Koivunen J, Haikarainen T, et al. Discovery of tankyrase inhibiting flavones with increased potency and isoenzyme selectivity. J Med Chem. 2013;56(20):7880-7889. doi: 10.1021/jm401463y
  28. Chen C, Xie L, Ren T, Huang Y, Xu J, Guo W. Immunotherapy for osteosarcoma: fundamental mechanism, rationale, and recent breakthroughs. Cancer Lett. 2021;500:1-10. doi: 10.1016/j.canlet.2020.12.024
  29. Park JA, Cheung NV. Promise and challenges of T cell immunotherapy for osteosarcoma. Int J Mol Sci. 2023;24(15):12520. doi: 10.3390/ijms241512520
  30. Zhu J, Fan J, Xia Y, et al. Potential targets and applications of nanodrug targeting myeloid cells in osteosarcoma for the enhancement of immunotherapy. Front Pharmacol. 2023;14:1271321. doi: 10.3389/fphar.2023.1271321
  31. Wu CC, Beird HC, Livingston JA, et al. Immuno-genomic landscape of osteosarcoma. Nat Commun. 2020;11(1):1008. doi: 10.1038/s41467-020-14646-w
  32. Tawbi HA, Burgess M, Bolejack V, et al. Pembrolizumab in advanced soft-tissue sarcoma and bone sarcoma (SARC028): a multicentre, two-cohort, single-arm, open-label, phase 2 trial. Lancet Oncol. 2017;18(11):1493-1501. doi: 10.1016/S1470-2045(17)30624-1
  33. Marinoff AE, Nathrath M, Shulman DS, et al. An international framework for clinical translation of molecular classifiers in osteosarcoma. NPJ Precis Oncol. 2026;10(1). doi: 10.1038/s41698-026-01456-4
  34. Moquin-Beaudry G, Marques Da Costa ME, Khneisser P, et al. Spatial transcriptomic atlas of aggressive osteosarcomas reveals shared immune landscape and targetable surface markers. Nat Commun. 2026;17(1). doi: 10.1038/s41467-026-74603-x
  35. Lacinski RA, Dziadowicz SA, Melemai VK, et al. Spatial multiplexed immunofluorescence analysis reveals coordinated cellular networks associated with overall survival in metastatic osteosarcoma. Bone Res. 2024;12(1):55. doi: 10.1038/s41413-024-00359-z
  36. Riley RD, Ensor J, Snell KIE, et al. Calculating the sample size required for developing a clinical prediction model. BMJ. 2020;368:m441. doi: 10.1136/bmj.m441
  37. Polley MYC, Dignam JJ. Statistical considerations in the evaluation of continuous biomarkers. J Nucl Med. 2021;62(5):605-611. doi: 10.2967/jnumed.120.251520
  38. Avila Cobos F, Alquicira-Hernandez J, Powell JE, Mestdagh P, De Preter K. Benchmarking of cell type deconvolution pipelines for transcriptomics data. Nat Commun. 2020;11(1):5650. doi: 10.1038/s41467-020-19015-1
  39. White BS, de Reyniès A, Newman AM, et al. Community assessment of methods to deconvolve cellular composition from bulk gene expression. Nat Commun. 2024;15(1):7362. doi: 10.1038/s41467-024-50618-0
  40. Rahnenführer J, De Bin R, Benner A, et al. Statistical analysis of high-dimensional biomedical data: a gentle introduction to analytical goals, common approaches and challenges. BMC Med. 2023;21(1):182. doi: 10.1186/s12916-023-02858-y
  41. Chen F, Zhang Z, Shen R, Chen M, Li G, Zhu X. Generation and characterization of patient-derived xenografts from patients with osteosarcoma. Tissue Cell. 2022;79:101911. doi: 10.1016/j.tice.2022.101911
  42. He A, Huang Y, Cheng W, et al. Organoid culture system for patient-derived lung metastatic osteosarcoma. Med Oncol. 2020;37(11):105. doi: 10.1007/s12032-020-01429-y
Share
Back to top
Eurasian Journal of Medicine and Oncology, Electronic ISSN: 2587-196X Print ISSN: 2587-2400, Published by AccScience Publishing